THE S&P 500 edged higher while the Nasdaq dipped after a volatile session on Tuesday as investors gauged inflation data and braced for quarterly earnings reports to justify stock valuations and the ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Stocks received an initial boost after a Labor Department report showed the producer price index rose moderately in December ...

Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 503.77% and ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Eli Lilly cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company sees healthy growth in 2025 due to the success of ...

Big Pharma is hiding a massive secret about so-called miracle weight-loss drugs like Ozempic – they come with a raft of ...